-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 7, Daiichi Sankyo and AstraZeneca announced the TROP2 targeted antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062a) in the phase 1 trial of TROPION-PanTumor01 to treat triple-negative breast cancer (TNBC) latest data
TNBC accounts for approximately 10% to 15% of breast cancer cases.
TROPION-PanTumor01 is an open-label, multi-center, first-in-human phase 1 clinical trial to evaluate the safety, tolerability and preliminary efficacy of Dato-DXd for advanced or metastatic solid tumors.
According to a blinded independent central review and evaluation, after a median follow-up of 7.
From: Daiichi Sankyo's official website
Subgroup analysis showed that among 27 patients with measurable lesions who had not received ADC treatment, the median follow-up was 8.
In terms of safety, the overall safety of Dato-DXd in TROPION-PanTumor01 is consistent with previous reports, and there is no new safety signal
Dr.
Currently, according to the Insight database, Dato-DXd has 2 phase 3 clinical trials in progress, targeting NSCLC and HR-positive/HER2-negative breast cancer respectively
From: Insight database (http://db.
Note: The original text has been deleted
